Status:
WITHDRAWN
Anti-rheumatic Drug Use and Risk of COVID-19 Infection in Rheumatoid Arthritis Patients
Lead Sponsor:
Sadat City University
Conditions:
Rheumatoid Arthritis
COVID
Eligibility:
All Genders
18-60 years
Brief Summary
Rheumatoid arthritis (RA) patients have an underlying immune deficiency and typically treated with immunosuppressive drugs, which may increase the risk of COVID-19 infection. Hydroxychloroquine (HCQ) ...
Eligibility Criteria
Inclusion
- \- Data of all definite cases of RA were collected and reviewed from complete medical records of patients by a team that included 2 trained physicians using a pretested data collection form.
Exclusion
- The exclusion criteria were included incomplete medical records or those with difficulty to communicate with the patients.
- Patients with acute lethal organ injury (e.g., acute myocardial infarction, acute coronary syndrome, acute pulmonary embolism, or acute stroke)
- Patients with decompensated or end stage chronic organ dysfunction (e.g., decompensated cirrhosis, decompensated chronic renal insufficiency, or severe congestive heart failure), diabetes mellitus, data of pregnant females, acquired immune deficiency syndrome (aids), and leukemia or other malignancies.
Key Trial Info
Start Date :
March 20 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 30 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04434118
Start Date
March 20 2020
End Date
December 30 2021
Last Update
May 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine
Shibīn al Kawm, Egypt